Efficacy

Lorviqua (lorlatinib) Efficacy in Lung Cancer

Lorviqua, also known by its generic name lorlatinib, is a medication specifically approved for the treatment of anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) in patients who have progressed on prior ALK inhibitors. As a third-generation ALK inhibitor, lorlatinib has shown significant efficacy in overcoming resistance to earlier ALK-targeted therapies. Clinical trials have demonstrated that lorlatinib is effective in inducing responses in a majority of patients with ALK-positive NSCLC, including those with central nervous system (CNS) metastases, which is a common complication in lung cancer and a challenge to treat.

The efficacy of Lorviqua was evaluated in a non-randomized, dose-ranging and activity-estimating, multi-cohort, multicenter study. The results indicated that lorlatinib provided a high overall response rate (ORR) in patients who had received one or more ALK inhibitors previously. The duration of response (DOR) and progression-free survival (PFS) rates were also significant, suggesting that lorlatinib is a potent option for patients with ALK-positive metastatic NSCLC, especially after the failure of other treatments.

Exkivity (mobocertinib) Efficacy in Lung Cancer

Exkivity, or mobocertinib, is a kinase inhibitor approved for the treatment of adult patients with metastatic NSCLC harboring epidermal growth factor receptor (EGFR) exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. This patient population has historically had limited treatment options, and mobocertinib represents a targeted therapy designed to address this specific genetic alteration. Clinical trials have shown that Exkivity has the ability to provide clinically meaningful responses in patients with EGFR exon 20 insertion-positive NSCLC.

The approval of Exkivity was based on the results of a multicenter, open-label, single-arm clinical trial, which showed a significant ORR in patients treated with mobocertinib. The efficacy endpoints also included DOR and PFS, which supported the therapeutic benefit of mobocertinib for patients with this challenging form of lung cancer. The data suggest that Exkivity offers a new line of hope for patients with EGFR exon 20 insertion-positive metastatic NSCLC, particularly for those who have limited treatment options after chemotherapy.